Author(s): Tanja Nicole Hartmann, Lisa Pleyer, Petra Desch, Alexander Egle, Richard Greil
Specialty: Oncology, Cell Biology, Immunology
Institution: Laboratory for Immunological and Molecular Cancer Research, IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University
Address: Salzburg, 5020, Austria
Published on October 13, 2009
Abstract: Chronic lymphocytic leukemia (CLL) is a malignancy mainly affecting elderly people and is still considered an incurable disease. Despite recent advances in CLL treatment, relapse rates are high and often accompanied by the development of resistance towards conventional chemotherapy. Thus, new agents are needed for the treatment of these patients. In recent years, our understanding of the biological mechanisms driving CLL pathogenesis has considerably improved, and novel treatment strategies are arising. This review summarizes recent insights in CLL biology and describes several new agents and treatment strategies that are currently explored in pre-clinical studies and early-phase clinical trials. ...
Read more
Author(s): Michael Dean
Institution: Laboratory of Genomic Diversity, National Cancer Institute-Frederick
Address: Frederick, MD, 21702, USA
Published on July 25, 2009
Abstract: Most current drug treatments cannot cure cancer. Recent studies have demonstrated that one of the reasons is that chemoagents kill the rapidly growing cells, including cancer cells, but do little damage to non-dividing cells. Cancerous stem cells stay quiescent and escape from these chemoagents to mount a comeback at a later time. ...
Read more